Bajaj Healthcare Ltd vs Gujarat Themis Biosyn Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Bajaj Healthcare Ltd is ₹ 335.2 as of 06 May 15:30 . The P/E Ratio of Bajaj Healthcare Ltd changed from 7.8 on March 2021 to 53.7 on March 2025 . This represents a CAGR of 47.09% over 5 yearsThe P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 years The Market Cap of Bajaj Healthcare Ltd changed from ₹ 650.77 crore on March 2021 to ₹ 2121 crore on March 2025 . This represents a CAGR of 26.66% over 5 yearsThe Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 years The revenue of Bajaj Healthcare Ltd for the Dec '25 is ₹ 162.87 crore as compare to the Sep '25 revenue of ₹ 149.57 crore. This represent the growth of 8.89% The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The ebitda of Bajaj Healthcare Ltd for the Dec '25 is ₹ 31.9 crore as compare to the Sep '25 ebitda of ₹ 27.26 crore. This represent the growth of 17.02% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The net profit of Bajaj Healthcare Ltd changed from ₹ 7.13 crore to ₹ 15.67 crore over 7 quarters. This represents a CAGR of 56.83% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The Dividend Payout of Bajaj Healthcare Ltd changed from 4.57 % on March 2021 to 7.99 % on March 2025 . This represents a CAGR of 11.82% over 5 yearsThe Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 years .

About Bajaj Healthcare Ltd

Incorporated in 1993, Maharashtra-based Bajaj Healthcare Limited is one of India's large scale and vertically integrated pharmaceutical manufacturer for quality-conscious customers.
The Company is engaged in the manufacturing and exporting of Active Pharmaceutical Ingredient (APIs), Intermediates, Finished Dosage Forms & Nutraceuticals. Company commenced its operations in 1993 with a single unit at Tarapur.
It became a public company in 2005 and listed its shares in the Indian stock exchanges in 2016. With Headquartered in Thane, Company has established 3 API plants in Gujarat and Maharashtra.
It has 4 units for APIs/ intermediates and one unit for formulation, which are designed to meet the requirements of both advanced as well as emerging market opportunities.
In 2008, the Company acquired Formulations plant at Manjusar, Vadodara and have converted it into WHO-GMP compliant facility.

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

FAQs for the comparison of Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd

Which company has a larger market capitalization, Bajaj Healthcare Ltd or Gujarat Themis Biosyn Ltd?

Market cap of Bajaj Healthcare Ltd is 1,128 Cr while Market cap of Gujarat Themis Biosyn Ltd is 4,125 Cr

What are the key factors driving the stock performance of Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd?

The stock performance of Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd?

As of May 6, 2026, the Bajaj Healthcare Ltd stock price is INR ₹335.2. On the other hand, Gujarat Themis Biosyn Ltd stock price is INR ₹378.6.

How do dividend payouts of Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd compare?

To compare the dividend payouts of Bajaj Healthcare Ltd and Gujarat Themis Biosyn Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.